Company intelligence / Profile preview

BeiZhen Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

BeiZhen Biotechnology is a China-based biotechnology company focused on the discovery and development of innovative therapies for oncology and autoimmune diseases. The company leverages its expertise in molecular biology and immunology to develop a pipeline of small molecules and biologics targeting well-validated pathways such as PD-1 and CTLA-4. BeiZhen aims to address significant unmet medical needs by providing high-quality, affordable therapeutic options for patients globally. Currently, the company is advancing several programs through the pre-clinical stage, with a focus on optimizing lead candidates for clinical entry.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibodyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on BeiZhen Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeiZhen Biotechnology.

Explore the full profile